Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Creating the next generation of cancer treatments
Investor & Media
Press ReleasesIn the NewsPublicationsEvents & PresentationsStock Information
SEC FilingsAnnual ReportsGovernanceTransfer Agent


November 24, 2014

Arno Therapeutics to Present at LD Micro Conference 2014

FLEMINGTON, NJ - November 24, 2014 - Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Alex Zukiwski, M.D., is scheduled to present at the Annual LD Micro Conference, being held December 2-4, 2014 at the Luxe Hotel in Los Angeles, CA.

Dr. Zukiwski will present on Thursday, December 4, 2014 at 12:30 p.m. PT to attending investors. During his presentation, Dr. Zukiwski will discuss Arno's business and growth strategy, latest clinical developments and anticipated milestones for its lead oncology candidate, onapristone.

Details of the presentation are as follows:
    Date: Thursday, December 4, 2014
    Time: 12:30 p.m. PT
    Track: Two
    Location: Luxe Hotel, Los Angeles, CA
ttending investors who would like to schedule a 1-on-1 meeting with Arno management during the conference may do so by contacting Lee Roth ( or Joseph Green ( of The Ruth Group.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit


The Ruth Group

Lee Roth (investors)
(646) 536-7012

Kirsten Thomas (media)
(646) 536-7014

Arno Therapeutics
Lawrence Kenyon
(862) 703-7171

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax